Director at Twist Bioscience (TWST) sells 1,000 shares in Rule 10b5-1 plan trade

Rhea-AI Filing Summary

Twist Bioscience director Melissa A. Starovasnik executed an open-market sale of 1,000 shares of Common Stock at $51.00 per share on April 1, 2026. After the transaction, she directly holds 25,722 shares of Twist Bioscience common stock.

The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the transaction was planned in advance rather than timed discretionarily.

Insights

Insider trading and governance analyst

Small, pre-planned director sale with substantial holdings remaining.

Director Melissa A. Starovasnik sold 1,000 shares of Twist Bioscience common stock at $51.00 per share in an open-market transaction on April 1, 2026. This is the only transaction reported and involves non-derivative common stock.

Following the sale, she directly owns 25,722 shares, so the transaction represents a relatively small portion of her disclosed position. The footnote specifies the sale occurred under a pre-established Rule 10b5-1 trading plan adopted on November 22, 2025, suggesting routine portfolio management rather than opportunistic market timing.

There are no derivative positions listed in this filing, and no exercises, gifts, or tax-withholding events reported. Overall, this appears to be a modest, pre-planned liquidity event with limited implications for the broader investment case based solely on this disclosure.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares ($51,000)

Net Sell 1 txn

Insider Starovasnik Melissa A.

Role Director

Sold 1,000 shs ($51K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$51.00	$51K

Holdings After Transaction: Common Stock — 25,722 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 1,000 shares Sale price: $51.00 per share Approximate transaction value: $51,000 +2 more

5 metrics

Shares sold 1,000 shares Open-market sale of common stock on April 1, 2026

Sale price $51.00 per share Price for the 1,000-share open-market sale

Approximate transaction value $51,000 1,000 shares sold at $51.00 each

Shares held after transaction 25,722 shares Director’s direct holdings following the sale

Net buy/sell shares -1,000 shares transactionSummary netBuySellShares for this Form 4

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4

3 terms

Rule 10b5-1 trading plan financial

"transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Starovasnik Melissa A.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S(1)		1,000	D	$51	25,722	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on November 22, 2025.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Melissa A. Starovasnik	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Twist Bioscience (TWST) report for Melissa A. Starovasnik?

Twist Bioscience reported that director Melissa A. Starovasnik sold 1,000 shares of common stock at $51.00 per share. The sale occurred on April 1, 2026 as an open-market transaction, and was disclosed in a Form 4 filing.

How many Twist Bioscience (TWST) shares does Melissa A. Starovasnik hold after the sale?

After the reported sale, Melissa A. Starovasnik directly holds 25,722 shares of Twist Bioscience common stock. This indicates the 1,000-share transaction reduced her position only modestly, leaving a substantial remaining stake disclosed in the Form 4.

Was the Twist Bioscience (TWST) insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 22, 2025. Such plans are pre-arranged trading programs designed to allow insiders to sell shares on a scheduled basis.

What type of transaction did Twist Bioscience (TWST) disclose in this Form 4?

The filing shows an open-market sale of common stock, coded “S” for sale. It involved 1,000 shares at $51.00 each on April 1, 2026, and is categorized as a non-derivative transaction with direct ownership.

Does this Twist Bioscience (TWST) Form 4 include any option exercises or derivative transactions?

No. The Form 4 indicates no derivative transactions, with zero exercises or other derivative activity reported. All disclosed activity relates to a single sale of common stock, and the derivativeSummary section is empty in this filing.